CHOOSE FDA-APPROVED OMIDRIA FOR PROVEN SAFETY

OMIDRIA demonstrated ocular adverse reaction rates similar to placebo¹

Ocular adverse reactions reported by ≥2% of subjects*

Ocular Events	OMIDRIA (n=459)	Placebo (n=462)
Anterior chamber inflammation	111 (24%)	102 (22%)
Increased intraocular pressure	20 (4%)	15 (3%)
Posterior capsule opacification	18 (4%)	16 (4%)
Eye irritation	9 (2%)	6 (1%)
Foreign body sensation in eye	8 (2%)	11 (2%)

^*Combined clinical trial results from 3 randomized, placebo-controlled studies. These adverse event rates may not reflect the rates observed in practice.

OMIDRIA demonstrated ocular adverse reaction rates similar to placebo as reported in the combined clinical trial results from 3 randomized, placebo-controlled studies.¹

Learn about the potential risks of compounded products

REFERENCE: 1. OMIDRIA [package insert]. Bellevue, WA: Rayner Surgical Inc. 2023.

INDICATIONS AND USAGE

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

IMPORTANT SAFETY INFORMATION

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure to phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

INDICATIONS AND USAGE

IMPORTANT SAFETY INFORMATION

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure to phenylephrine may cause elevations in blood pressure.

The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

CHOOSE FDA-APPROVED OMIDRIA FOR PROVEN SAFETY

OMIDRIA demonstrated ocular adverse reaction rates similar to placebo1

Ocular adverse reactions reported by ≥2% of subjects*

Important Safety Information

Indications and Usage

Click below to Continue or Cancel to stay on this page.

OMIDRIA demonstrated ocular adverse reaction rates similar to placebo¹